| CareFirst BlueCross BlueShield (CareFirst) and Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in molecular diagnostics and personalized medicine, today announced that they have signed an agreement to collaborate on a clinical utility study for the Vectra® DA test in patients with rheumatoid arthritis (RA). Vectra DA is a pioneering test designed to predict whether patients with RA are at risk for radiographic progression (RP) so that rheumatologists can optimize treatment decisions. ... |